Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06947980
PHASE2

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-06-19

Completion Date

2026-11-07

Last Updated

2025-08-17

Healthy Volunteers

No

Interventions

DRUG

Placebo Comparator

Placebo subcutaneous injection

BIOLOGICAL

CM512

CM512 subcutaneous injection

Locations (1)

Peking University People's hospital

Beijing, China